 |
 |

DRESS Syndrome Associated With Nevirapine Therapy
Arch Intern Med. 2001;161:2501-2502.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or
hypersensitive syndrome has been associated with the use of aromatic anticonvulsants,
sulfonamides, calcium channel blockers, allopurinol, ranitidine, and thalidomide.
The clinical manifestations include a diffuse maculopapular rash, fever, multivisceral
involvement, eosinophilia, atypical lymphocytosis, and abnormal liver function
test results.1
Nevirapine is a potent and selective noncompetitive inhibitor of the
reverse transcriptase enzyme of human immunodeficiency virus (HIV) type 1,
inhibiting reverse transcriptase by binding to tyrosine components of the
enzyme, which are located near the catalytic site.2
It was the first nonnucleoside reverse transcriptase inhibitor approved for
clinical use in patients infected with HIV and is used in combination with
other antiretroviral agents.3-4
Two cases of DRESS syndrome induced by the use of zalcitabine5 have been reported, and 4 cases were associated
with nevirapine therapy.6-7
The following is a report of a new case of DRESS syndrome associated with
nevirapine . . . [Full Text of this Article] Report of a Case
Comment
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Drug Rash With Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity With a Nevirapine-Containing Regimen in a Pregnant Patient With Human Immunodeficiency Virus
Knudtson et al.
Obstet Gynecol 2003;101:1094-1097.
ABSTRACT
| FULL TEXT
|